Top Page
Alterity Therapeutics
(Sydney:ATH)
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Alterity Therapeutics Business Overview & Revenue Model
Alterity Therapeutics Financial Statement Overview
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -14.63M | -19.46M | -17.51M | -17.39M | -19.36M |
| Net Income | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | |||||
| Total Assets | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | |||||
| Free Cash Flow | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$72.45M | 25.12 | 27.24% | 2.81% | 0.65% | -9.90% | |
52 Neutral | AU$156.16M | -4.74 | ― | ― | ― | 0.66% | |
52 Neutral | AU$98.99M | -11.71 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$114.21M | -2.91 | -81.03% | ― | -20.79% | 73.98% | |
42 Neutral | AU$77.16M | -1.07 | -83.09% | ― | ― | 55.94% | |
41 Neutral | AU$87.00M | -6.67 | -42.68% | ― | ― | 63.46% |
Alterity Therapeutics Corporate Events
Alterity Therapeutics reported a sharp increase in half-year revenue to A$909,750 for the six months to 31 December 2025, driven entirely by higher interest income on its bank balances, while remaining a pre-revenue biotech with no dividend payments. The company’s net loss widened 34% to A$9.6 million compared with the prior corresponding period, but net tangible asset backing rose to 0.50 cents per share from 0.14 cents, signaling a stronger balance sheet despite ongoing losses and unchanged corporate structure.
Management noted that the detailed drivers of the loss are outlined in its review of operations, and the interim financial statements have been reviewed by an independent auditor, offering additional assurance to investors. With no changes in controlled entities and no distributions declared, the update highlights Alterity’s continued focus on funding and executing its development programs while absorbing significant operating expenses typical of early-stage biotechnology companies.
The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics reported a robust second quarter of FY26, highlighting strengthened Phase 2 data for its lead MSA candidate ATH434, further detailed through additional analyses and multiple international scientific presentations that reinforced a potential US$2.4 billion commercial opportunity. The company advanced regulatory preparations toward a pivotal Phase 3 program, including work toward an End-of-Phase-2 meeting with the U.S. FDA targeted for mid-2026, while refining trial design and operational readiness, exploring non-dilutive funding partnerships with pharmaceutical and corporate advisers, bolstering its board and executive leadership, and maintaining a solid cash balance of A$49.2 million to support its next stage of clinical and commercial development.
The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics reported that it successfully completed its Phase 2 clinical program for lead candidate ATH434 in multiple system atrophy during 2025, with data showing the drug was safe, well-tolerated, and associated with slowing disease progression across several clinical endpoints, including functional measures, mobility, and orthostatic hypotension. Building on these results, the company is now preparing for an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize a Phase 3 trial design, scaling its clinical, manufacturing, and regulatory infrastructure and deepening engagement with key neurologists, while also strengthening its board and leadership team to support potential late-stage development and future commercialization.
The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics Limited has notified the market of the issue of 43.5 million unlisted options under an employee incentive scheme, with an exercise price of US$0.0057 and an expiry date of 13 January 2031. The options, which will not be quoted on the ASX, reflect the company’s continued use of equity incentives to align employees with shareholder interests and may contribute to future dilution if exercised, signaling an ongoing focus on incentivising key personnel during its development phase.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics has notified the market of the issue of 18 million unlisted options under its employee incentive scheme, each exercisable at $0.008 and expiring on 9 January 2031. The move expands the company’s pool of unquoted equity-based incentives, signalling continued reliance on options to motivate employees and align staff interests with long-term shareholder value, while incrementally increasing potential future dilution for existing investors.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics has released a brief corporate communication noting that some of its January 2026 corporate presentation may include statements that qualify as forward-looking under U.S. securities laws. The company cautions that such statements, including any financial projections or discussions of strategic plans and objectives, are subject to risks and uncertainties that could cause actual results to differ materially, and it directs investors to its 2025 Form 20-F risk factors for further detail, underscoring the regulatory and risk-awareness context around its investor communications.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics has announced the expiry of 91,392,720 unexercised options (ASX code ATHAAD) with an exercise price of A$0.032, which lapsed on 6 January 2026. The cessation of these options removes a substantial block of potential dilution from the company’s capital structure, slightly simplifying its issued capital and clarifying the near‑term equity overhang for existing shareholders and prospective investors.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.